Style | Citing Format |
---|---|
MLA | Shirinyfard Pilehrood K, et al.. "Elevated Risk of Possible Sarcopenia and Weak Muscle Strength With Higher Dietary Inflammatory Index in Iranian Breast Cancer Survivors: A Cross-Sectional Study." BMC Nutrition, vol. 11, no. 1, 2025, pp. -. |
APA | Shirinyfard Pilehrood K, Askari G, Sharifi M, Kargarfard M, Sarafbank S (2025). Elevated Risk of Possible Sarcopenia and Weak Muscle Strength With Higher Dietary Inflammatory Index in Iranian Breast Cancer Survivors: A Cross-Sectional Study. BMC Nutrition, 11(1), -. |
Chicago | Shirinyfard Pilehrood K, Askari G, Sharifi M, Kargarfard M, Sarafbank S. "Elevated Risk of Possible Sarcopenia and Weak Muscle Strength With Higher Dietary Inflammatory Index in Iranian Breast Cancer Survivors: A Cross-Sectional Study." BMC Nutrition 11, no. 1 (2025): -. |
Harvard | Shirinyfard Pilehrood K et al. (2025) 'Elevated Risk of Possible Sarcopenia and Weak Muscle Strength With Higher Dietary Inflammatory Index in Iranian Breast Cancer Survivors: A Cross-Sectional Study', BMC Nutrition, 11(1), pp. -. |
Vancouver | Shirinyfard Pilehrood K, Askari G, Sharifi M, Kargarfard M, Sarafbank S. Elevated Risk of Possible Sarcopenia and Weak Muscle Strength With Higher Dietary Inflammatory Index in Iranian Breast Cancer Survivors: A Cross-Sectional Study. BMC Nutrition. 2025;11(1):-. |
BibTex | @article{ author = {Shirinyfard Pilehrood K and Askari G and Sharifi M and Kargarfard M and Sarafbank S}, title = {Elevated Risk of Possible Sarcopenia and Weak Muscle Strength With Higher Dietary Inflammatory Index in Iranian Breast Cancer Survivors: A Cross-Sectional Study}, journal = {BMC Nutrition}, volume = {11}, number = {1}, pages = {-}, year = {2025} } |
RIS | TY - JOUR AU - Shirinyfard Pilehrood K AU - Askari G AU - Sharifi M AU - Kargarfard M AU - Sarafbank S TI - Elevated Risk of Possible Sarcopenia and Weak Muscle Strength With Higher Dietary Inflammatory Index in Iranian Breast Cancer Survivors: A Cross-Sectional Study JO - BMC Nutrition VL - 11 IS - 1 SP - EP - PY - 2025 ER - |